Inhaled nitric oxide had significant antibacterial activity against Mycobacterium abscessus (M. abscessus), which can infect the airways of patients with cystic fibrosis, according to AIT Therapeutics.

Mycobacterium abscessus complex (MABSC) comprises a group of rapidly growing, multidrug-resistant species of nontuberculous mycobacteria.

AIT investigated in vitro the sensitivity of several multidrug-resistant clinical isolates of M. abscessus to NO, which was delivered at specific concentrations using a custom-designed NO delivery system.

Results indicated that there was significant dose-dependent antibacterial activity of high-dose NO against numerous multidrug-resistant clinical isolates of M. abscessus.

Read more at www.cysticfibrosisnewstoday.com